{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:34:26Z","timestamp":1780612466932,"version":"3.54.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02383-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:03:14Z","timestamp":1751410994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative multi-omic analysis of NLRP3 inflammasome dysregulation and subtyping for personalized treatment in acute myeloid leukemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Hong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"2383_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606. https:\/\/doi.org\/10.1016\/S0140-6736(18)31041-9.","journal-title":"Lancet"},{"key":"2383_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502\u201326. https:\/\/doi.org\/10.1002\/ajh.26822.","journal-title":"Am J Hematol"},{"key":"2383_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"2383_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27625","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.27625.","journal-title":"Am J Hematol"},{"key":"2383_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"key":"2383_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s10875-010-9440-3","volume":"30","author":"C Jin","year":"2010","unstructured":"Jin C, Flavell RA. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol. 2010;30:628\u201331. https:\/\/doi.org\/10.1007\/s10875-010-9440-3.","journal-title":"J Clin Immunol"},{"key":"2383_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2326-6066.CIR-16-0269","volume":"5","author":"R Karki","year":"2017","unstructured":"Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res. 2017;5:94\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0269.","journal-title":"Cancer Immunol Res"},{"key":"2383_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1084\/jem.20100050","volume":"207","author":"IC Allen","year":"2010","unstructured":"Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207:1045\u201356. https:\/\/doi.org\/10.1084\/jem.20100050.","journal-title":"J Exp Med"},{"key":"2383_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"key":"2383_CR10","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jordao MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1808.","journal-title":"Cancer Discov"},{"key":"2383_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/sj.leu.2401634","volume":"14","author":"M Filipits","year":"2000","unstructured":"Filipits M, Stranzl T, Pohl G, Heinzl H, Jager U, Geissler K, et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia. 2000;14:68\u201376. https:\/\/doi.org\/10.1038\/sj.leu.2401634.","journal-title":"Leukemia"},{"key":"2383_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13:155. https:\/\/doi.org\/10.1186\/s13045-020-00992-1.","journal-title":"J Hematol Oncol"},{"key":"2383_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.3283","volume":"47","author":"SW Paugh","year":"2015","unstructured":"Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet. 2015;47:607\u201314. https:\/\/doi.org\/10.1038\/ng.3283.","journal-title":"Nat Genet"},{"key":"2383_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa345","author":"M Ju","year":"2021","unstructured":"Ju M, Bi J, Wei Q, Jiang L, Guan Q, Zhang M, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform. 2021. https:\/\/doi.org\/10.1093\/bib\/bbaa345.","journal-title":"Brief Bioinform"},{"key":"2383_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0546-8.","journal-title":"Nat Biotechnol"},{"key":"2383_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","volume":"35","author":"J Vivian","year":"2017","unstructured":"Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35:314\u20136. https:\/\/doi.org\/10.1038\/nbt.3772.","journal-title":"Nat Biotechnol"},{"key":"2383_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"key":"2383_CR18","unstructured":"Kassambara A, Kosinski M & Biecek P. survminer: drawing survival curves using \u2018ggplot2\u2019; 2021."},{"key":"2383_CR19","unstructured":"Therneau TM. A package for survival analysis in R; 2023."},{"key":"2383_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","journal-title":"BMC Bioinform"},{"key":"2383_CR21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btq170.","journal-title":"Bioinformatics"},{"key":"2383_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03610927408827101","volume":"3","author":"T Cali\u0144ski","year":"1974","unstructured":"Cali\u0144ski T, Harabasz J. A dendrite method for cluster analysis. Commun Stat. 1974;3:1\u201327. https:\/\/doi.org\/10.1080\/03610927408827101.","journal-title":"Commun Stat"},{"key":"2383_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ajhg.2008.02.013","volume":"82","author":"S Kohler","year":"2008","unstructured":"Kohler S, Bauer S, Horn D, Robinson PN. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet. 2008;82:949\u201358. https:\/\/doi.org\/10.1016\/j.ajhg.2008.02.013.","journal-title":"Am J Hum Genet"},{"key":"2383_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1257601","volume":"347","author":"J Menche","year":"2015","unstructured":"Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347: 1257601. https:\/\/doi.org\/10.1126\/science.1257601.","journal-title":"Science"},{"key":"2383_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1\u201322.","journal-title":"J Stat Softw"},{"key":"2383_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385\u201395. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19970228)16:4%3c385::aid-sim380%3e3.0.co;2-3.","journal-title":"Stat Med"},{"key":"2383_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00277-020-04358-y","volume":"100","author":"YH Wang","year":"2021","unstructured":"Wang YH, Lin CC, Hsu CL, Hung SY, Yao CY, Lee SH, et al. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. Ann Hematol. 2021;100:487\u201398. https:\/\/doi.org\/10.1007\/s00277-020-04358-y.","journal-title":"Ann Hematol"},{"key":"2383_CR28","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1200\/JCO.2012.44.3184","volume":"31","author":"Z Li","year":"2013","unstructured":"Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol. 2013;31:1172\u201381. https:\/\/doi.org\/10.1200\/JCO.2012.44.3184.","journal-title":"J Clin Oncol"},{"key":"2383_CR29","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381\u201397. https:\/\/doi.org\/10.1002\/sim.5958.","journal-title":"Stat Med"},{"key":"2383_CR30","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"key":"2383_CR31","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"key":"2383_CR32","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8:1738. https:\/\/doi.org\/10.1038\/s41467-017-01460-0.","journal-title":"Nat Commun"},{"key":"2383_CR33","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0136-1.","journal-title":"Nat Med"},{"key":"2383_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140179","author":"JK Bailur","year":"2020","unstructured":"Bailur JK, McCachren SS, Pendleton K, Vasquez JC, Lim HS, Duffy A, et al. Risk-associated alterations in marrow T cells in pediatric leukemia. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.140179.","journal-title":"JCI Insight"},{"key":"2383_CR35","doi-asserted-by":"publisher","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","volume":"51","author":"Y Han","year":"2023","unstructured":"Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J, et al. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2023;51:D1425\u201331. https:\/\/doi.org\/10.1093\/nar\/gkac959.","journal-title":"Nucleic Acids Res"},{"key":"2383_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42:293\u2013304. https:\/\/doi.org\/10.1038\/s41587-023-01767-y.","journal-title":"Nat Biotechnol"},{"key":"2383_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6.","journal-title":"Nat Commun"},{"key":"2383_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"issue":"271\u2013281","key":"2383_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 2018;6(271\u2013281): e277. https:\/\/doi.org\/10.1016\/j.cels.2018.03.002.","journal-title":"Cell Syst"},{"key":"2383_CR40","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356. https:\/\/doi.org\/10.1101\/gr.239244.118.","journal-title":"Genome Res"},{"key":"2383_CR41","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955-961. https:\/\/doi.org\/10.1093\/nar\/gks1111.","journal-title":"Nucleic Acids Res"},{"key":"2383_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034975","author":"A Kishtagari","year":"2021","unstructured":"Kishtagari A, Levine RL. The role of somatic mutations in acute myeloid leukemia pathogenesis. Cold Spring Harb Perspect Med. 2021. https:\/\/doi.org\/10.1101\/cshperspect.a034975.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2383_CR43","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136:1707\u201321. https:\/\/doi.org\/10.1182\/blood.2019004226.","journal-title":"Blood"},{"key":"2383_CR44","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352. https:\/\/doi.org\/10.1056\/NEJMra1406184.","journal-title":"N Engl J Med"},{"key":"2383_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101572","author":"B Caulier","year":"2024","unstructured":"Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, et al. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell Rep Med. 2024. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101572.","journal-title":"Cell Rep Med"},{"key":"2383_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02269-9","author":"A Karami","year":"2024","unstructured":"Karami A, Skorski T. DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02269-9.","journal-title":"Leukemia"},{"key":"2383_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1182\/blood-2018-02-834895","volume":"132","author":"S Maifrede","year":"2018","unstructured":"Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018;132:67\u201377. https:\/\/doi.org\/10.1182\/blood-2018-02-834895.","journal-title":"Blood"},{"key":"2383_CR48","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41375-020-0827-8","volume":"34","author":"MZ Ratajczak","year":"2020","unstructured":"Ratajczak MZ, Bujko K, Cymer M, Thapa A, Adamiak M, Ratajczak J, et al. The Nlrp3 inflammasome as a \u201crising star\u201d in studies of normal and malignant hematopoiesis. Leukemia. 2020;34:1512\u201323. https:\/\/doi.org\/10.1038\/s41375-020-0827-8.","journal-title":"Leukemia"},{"key":"2383_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12964-024-01777-6","volume":"22","author":"M Luciano","year":"2024","unstructured":"Luciano M, Sieberer H, Krenn PW, Dang HH, Vetter J, Neuper T, et al. Targeting NLRP3 inhibits AML progression by inducing PERK\/eIF2-mediated apoptosis. Cell Commun Signal. 2024;22:424. https:\/\/doi.org\/10.1186\/s12964-024-01777-6.","journal-title":"Cell Commun Signal"},{"key":"2383_CR50","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2023.13039","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xin C, Li X, Chang X, Jiang R. NLRP3 participates in the differentiation and apoptosis of PMA-treated leukemia cells. Mol Med Rep. 2023. https:\/\/doi.org\/10.3892\/mmr.2023.13039.","journal-title":"Mol Med Rep"},{"key":"2383_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042369","author":"IE Stergiou","year":"2024","unstructured":"Stergiou IE, Tsironis C, Papadakos SP, Tsitsilonis OE, Dimopoulos MA, Theocharis S. Unraveling the role of the NLRP3 inflammasome in lymphoma: implications in pathogenesis and therapeutic strategies. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042369.","journal-title":"Int J Mol Sci"},{"key":"2383_CR52","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.7150\/ijms.96627","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Hou Q, Chang T, Zheng J, Yao C, He J, et al. Analysis of prognostic biomarker models of TXNIP\/NLRP3\/IL1B inflammasome pathway in patients with acute myeloid leukemia. Int J Med Sci. 2024;21:1438\u201346. https:\/\/doi.org\/10.7150\/ijms.96627.","journal-title":"Int J Med Sci"},{"key":"2383_CR53","doi-asserted-by":"publisher","first-page":"14012","DOI":"10.1038\/s41598-024-64567-7","volume":"14","author":"Y Zhan","year":"2024","unstructured":"Zhan Y, Ma S, Zhang T, Zhang L, Zhao P, Yang X, et al. Identification of a novel monocyte\/macrophage-related gene signature for predicting survival and immune response in acute myeloid leukemia. Sci Rep. 2024;14:14012. https:\/\/doi.org\/10.1038\/s41598-024-64567-7.","journal-title":"Sci Rep"},{"key":"2383_CR54","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.celrep.2017.12.055","volume":"22","author":"Y Xiu","year":"2018","unstructured":"Xiu Y, Dong Q, Li Q, Li F, Borcherding N, Zhang W, et al. Stabilization of NF-kappaB-inducing kinase suppresses MLL-AF9-induced acute myeloid leukemia. Cell Rep. 2018;22:350\u20138. https:\/\/doi.org\/10.1016\/j.celrep.2017.12.055.","journal-title":"Cell Rep"},{"key":"2383_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.811144","volume":"13","author":"T Menter","year":"2022","unstructured":"Menter T, Tzankov A. Tumor microenvironment in acute myeloid leukemia: adjusting niches. Front Immunol. 2022;13: 811144. https:\/\/doi.org\/10.3389\/fimmu.2022.811144.","journal-title":"Front Immunol"},{"key":"2383_CR56","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","volume":"118","author":"C Ustun","year":"2011","unstructured":"Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084\u201395. https:\/\/doi.org\/10.1182\/blood-2011-07-365817.","journal-title":"Blood"},{"key":"2383_CR57","doi-asserted-by":"publisher","first-page":"23882","DOI":"10.1038\/s41598-024-74168-z","volume":"14","author":"BG Santos de Macedo","year":"2024","unstructured":"Santos de Macedo BG, Albuquerque de Melo M, Pereira-Martins DA, Machado-Neto JA, Traina F. Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia. Sci Rep. 2024;14:23882. https:\/\/doi.org\/10.1038\/s41598-024-74168-z.","journal-title":"Sci Rep"},{"key":"2383_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27600","author":"EC Chen","year":"2025","unstructured":"Chen EC, Shimony S, Luskin MR, Stone RM. Biology and management of acute myeloid leukemia with mutated NPM1. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.27600.","journal-title":"Am J Hematol"},{"key":"2383_CR59","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","volume":"106","author":"S Schnittger","year":"2005","unstructured":"Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733\u20139. https:\/\/doi.org\/10.1182\/blood-2005-06-2248.","journal-title":"Blood"},{"key":"2383_CR60","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","volume":"107","author":"C Thiede","year":"2006","unstructured":"Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011\u201320. https:\/\/doi.org\/10.1182\/blood-2005-08-3167.","journal-title":"Blood"},{"key":"2383_CR61","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-024-01103-w","volume":"14","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zhou Y, Zhuo N, Xie W, Meng H, Lou Y, et al. Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia. Blood Cancer J. 2024;14:118. https:\/\/doi.org\/10.1038\/s41408-024-01103-w.","journal-title":"Blood Cancer J"},{"key":"2383_CR62","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2001.19.10.2705","volume":"19","author":"U Creutzig","year":"2001","unstructured":"Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19:2705\u201313. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2705.","journal-title":"J Clin Oncol"},{"key":"2383_CR63","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","volume":"124","author":"A Spencer","year":"2014","unstructured":"Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124:2190\u20135. https:\/\/doi.org\/10.1182\/blood-2014-03-559963.","journal-title":"Blood"},{"key":"2383_CR64","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","volume":"3","author":"KH Lin","year":"2022","unstructured":"Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, et al. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat Cancer. 2022;3:837\u201351. https:\/\/doi.org\/10.1038\/s43018-022-00394-x.","journal-title":"Nat Cancer"},{"key":"2383_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-022-01264-w","volume":"15","author":"H Handa","year":"2022","unstructured":"Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, et al. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1\/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. J Hematol Oncol. 2022;15:56. https:\/\/doi.org\/10.1186\/s13045-022-01264-w.","journal-title":"J Hematol Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02383-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02383-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02383-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:03:15Z","timestamp":1751410995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02383-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02383-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"649"}}